Search

Frontiers in Medicinal Chemistry is a book series devoted to reviews on research topics relevant to medicinal chemistry and allied disciplines. Frontiers in Medicinal Chemistry covers developments in rational drug design, bioorganic chemistry, high-throughput screening, combinatorial chemistry, compound diversity measurements, drug absorption, drug distribution, metabolism, new and emerging drug targets, natural products, pharmacogenomics, chemoinformatics, and structure-activity relationships. This book series is essential for any medicinal chemist who wishes to be updated on the latest and the most important advances in the field.This is the tenth volume of the series. The extensive volume brings 11 reviews on a variety of topics including anti-cancer drug therapeutics, food chemistry, toxicology and drug development strategies. The list of topics in this volume includes: Isoxazole derivatives as potential pharmacophore for new drug development Contemporary trends in drug repurposing: identifying new targets for existing drugs Pharmaceutical potential of pyrimidines as antiviral agents Drugs and phytochemicals targeting cancer Harnessing the neurological properties of indian brain health booster brahmi Carcinogenicity of hexavalent chromium and its effects Medicinal plants: a future of modern medical system Shikonin, a naphthaquinone of commercial importance: its biosynthesis and prospect for use as drugs Fast foods: chemical composition and implications for health Implications of DNA-acting agents as anticarcinogenic potential in breast cancer therapeutics Aloe vera - a medicinal plant as potential therapeutic agents for liver cancer

The goal of this book is to provide a guide and detailed review of immunosuppression in terms of molecular mechanisms of action, side effects and clinical trials that validated their utility. This includes their use in solid organ transplantation, bone marrow transplantation and autoimmune diseases and inflammatory diseases. This book is a critical review of these topics and a vital resource.

‘ENHANZE® drug delivery technology: Advancing subcutaneous drug delivery using recombinant human hyaluronidase PH20'provides readers with in-depth information on the potential benefits and challenges of subcutaneous (SC) drug delivery, the biology of hyaluronan and hyaluronidases in the SC space, and a comprehensive overview on the history of hyaluronidases and the development of recombinant human hyaluronidase PH20 (rHuPH20). Current applications of rHuPH20 as well as approved biotherapeutics utilizing HuPH20-facilitated SC drug delivery are summarized, and the underlying non-clinical and clinical development approaches are introduced as a basis for future application to biologics in various disease areas. Table of Contents: • Introduction to subcutaneous drug delivery • Biology of hyaluronan and hyaluronidases in the subcutaneous space • History of hyaluronidases and development of rHuPH20 • The ENHANZE® platform: Clinical applications of a subcutaneous drug delivery technology • Application of ENHANZE® drug delivery technology: Development of currently marketed products

This book fills an important gap in the professional's daily practice of both Oncology and Hematology. From the understanding of oncological and hematological diseases, drugs and protocols, to the administration of an oncology pharmacy, this book is an essential guide to supporting health professionals working or that intend to work in this area. This golden standard to practice is featured as a pocket guide easy to be carried around the hospital or clinic. The chapters cover topics such as support drugs; immunotherapy; CART-cells; chemotherapy for rheumatology, surgery and ICU; tumor lysis; extravasation; adverse effects; and stem cell transplantation. The content gathered in this volume is an invaluable resource not only to oncologic, clinical and hospital pharmacists, but also residents, postgraduate and undergraduate students.

Topics in Anti-Cancer Research Volume 8 covers new developments in the field of cancer. Novel drugs as anticancer agents include natural and synthetic phenazines and other anti-cancer compounds. It also encompasses the role of estrogen as endocrine disruptors and strategies targeting cancer stem cells for the treatment of different types of cancers, including myeloma and renal cell cancer. The diversity of researches and topics published in this eBook Series will be valuable to cancer researchers, clinicians, and cancer professionals aiming to develop novel anti-cancer targets for the treatment of various cancers. The topics covered in the eighth volume of this series are as follows: -Novel Drugs for Multiple Myeloma -Synthetic Estrogens are Endocrine Disruptors via Inhibition of AF1 Domain of ERs -Recent Progress of Phenazines as Anticancer Agents -Cancer Stem Cell Targeting for Anticancer Therapy: Strategies and Challenges

A major objective of this book is to reveal unprecedented opportunities to understand and overcome drug resistance through the clinical assessment of rational therapeutic drug combinations and the use of predictive and prognostic biomarkers to enable patient stratification and tailor treatments. It offers to the readers an updated overview on the possible reasons of failure of new and promising therapeutic opportunities.

Epigenetics is one of the fastest moving fields in drug discovery, with almost every large pharmaceutical company and a substantial number of biotechnology companies targeting epigenetic processes to treat diseases ranging from cancer to Huntington's disease and from inflammation to sickle cell anaemia. The book is structured in three main sections. The first section introduces epigenetics and explain its importance at both a phenomenological and molecular level. The second section goes on to review how each of the big breakthroughs in drug discovery in this field have developed, with a strong emphasis on case histories. The final section highlights the ongoing challenges in creating safe and efficacious epigenetic drugs. Written and edited by experts within the field from both industry and academia, this book provides an invaluable guide to this developing field for medicinal chemists working in academia and in the pharmaceutical industry.

This book provides an unprecedented overview of'Targeted Therapies'for acute myeloid leukemias. It aims at an almost comprehensive coverage of the diverse therapeutic strategies that have been developed during the last decade and are now being evaluated in early clinical trials. Paired and authoritative chapters by leading research scientists and clinicians explain basic concepts and clinical translation of topics that include the underlying genetic and proteomic abnormalities of AML, the development of novel nucleoside analogues, the roles of microRNAs, apoptosis regulators Bcl-2 and p53 and of critical cell signaling proteins such as PIM, FLT3, Raf/MEK, PI3K/AKT/mTOR and aurora kinases. Chapters on epigenetic mechanisms, nuclear receptors, cell surface antigens, the hypoxic leukemia microenvironment, stem cells and leukemia metabolism provide insights into leukemia cell vulnerabilities. Cell therapies utilizing T-, NK- and mesenchymal stem cells and progress in hematopoietic transplantation strategies round up this overview of the multi-dimensional therapeutic landscape in which leukemia specialists develop treatment strategies that are expected to make'leukemia history'in the near future.